TAVR vs Open Heart Surgery for Aortic Stenosis by Age

Research-informed explainer — last updated April 12, 2026

For older adults and people who cannot safely undergo open-heart surgery, transcatheter aortic valve replacement (TAVR) produces survival outcomes at least as good as surgery with a much faster recovery. For younger adults in their 50s and 60s with severe aortic stenosis, surgery or TAVR are both viable options — but long-term valve durability, the risk of needing a repeat procedure, and individual anatomy all influence the best choice. This decision now turns heavily on age, surgical risk, and where you want to be in ten years.

This explainer draws on peer-reviewed research from interventional cardiologists and structural heart specialists listed in the Convene directory. Their published work includes the landmark PARTNER 1, 2, and 3 trials, the SURTAVI trial, and the standardized endpoint definitions that made rigorous cross-trial comparison possible.

What is aortic stenosis?

Aortic stenosis is a narrowing of the aortic valve — the one-way gate between your heart's main pumping chamber (the left ventricle) and the aorta. As calcium builds up on the valve leaflets over decades, the opening shrinks. The heart has to work harder to push blood through, and eventually it cannot keep up.

Symptoms typically emerge when the stenosis becomes severe: chest tightness with exertion, shortness of breath, dizziness, or fainting. Once symptoms appear, the outlook without intervention is poor — roughly half of patients die within two years. Treatment is replacement of the diseased valve, either through open-chest surgery or, in the last two decades, through a catheter.

What are the two procedures?

Surgical aortic valve replacement (SAVR) requires stopping the heart, going on cardiopulmonary bypass, opening the chest, removing the diseased valve, and sewing a new one in place. Recovery takes four to eight weeks. The procedure has a long track record — surgeons have been doing it since the 1960s — and modern mechanical and bioprosthetic valves are highly durable.

Transcatheter aortic valve replacement (TAVR) threads a compressed replacement valve through a catheter, typically entering through the femoral artery in the groin. Once positioned across the diseased valve, a balloon or self-expanding mechanism deploys the new valve. The heart keeps beating throughout. Most patients go home in one to two days and recover within a week. The first human TAVR was performed in 2002 by Alain Cribier, in research contributed to by investigators at Columbia University [5].

At a glance

What the PARTNER 1 trial showed (inoperable patients)

Before PARTNER, patients too sick for surgery had no good option. The PARTNER 1 trial enrolled 358 patients with severe aortic stenosis who were deemed inoperable and randomly assigned them to TAVR or standard therapy (which sometimes included balloon valvuloplasty). At one year, 30.7% of TAVR patients had died from any cause compared with 50.7% of standard-therapy patients — a 20 percentage point absolute reduction. TAVR also significantly reduced the rate of rehospitalization and cardiac symptoms [1].

The tradeoff was a higher rate of major stroke (5.0% vs 1.1% at 30 days) and major vascular complications (16.2% vs 1.1%). These rates reflected early-generation technology and technique; they have fallen substantially since. But for patients who had no surgical option, TAVR was transformative.

What PARTNER 1 and PARTNER 2 showed (high- and intermediate-risk patients)

The PARTNER 1B arm enrolled 699 high-risk surgical candidates (Society of Thoracic Surgeons score averaging 11.8%) and compared TAVR to SAVR. At one year, survival was similar: 24.2% of TAVR patients had died vs 26.8% of surgical patients — a non-significant difference. TAVR had higher vascular complication and paravalvular leak rates; surgery had higher rates of major bleeding and new atrial fibrillation [2].

The PARTNER 2 trial moved the evidence into intermediate surgical risk. Among 2,032 patients with STS scores averaging 5.8%, TAVR with a balloon-expandable valve produced rates of death or disabling stroke at two years of 19.3% vs 21.1% for surgery — statistically non-inferior. The result held across most anatomic subgroups [4].

What PARTNER 3 showed (low-risk patients)

The question that mattered most to younger and healthier patients was answered by PARTNER 3 in 2019. This trial enrolled 1,000 patients with severe aortic stenosis at low surgical risk (STS score under 4%) and randomized them to TAVR with a balloon-expandable valve vs surgery.

At one year, the composite of death, stroke, or rehospitalization occurred in 8.5% of TAVR patients vs 15.1% of surgical patients — a statistically significant advantage for TAVR [3]. TAVR patients had shorter hospital stays, less atrial fibrillation, and lower rates of acute kidney injury. Surgery patients had lower rates of new pacemaker implantation.

This result reshaped practice. TAVR is now FDA-approved for patients at all risk levels, including low risk. But the one-year advantage for TAVR in PARTNER 3 has narrowed in longer follow-up. The durability question — whether TAVR valves last as long as surgical valves — is the critical unknown for younger patients.

The durability problem and why age matters

Surgical bioprosthetic valves have 15- to 20-year follow-up data showing that about 80–90% function without structural deterioration at 10 years. TAVR valves have strong 5-year data and increasingly solid 8- to 10-year data, but the long-term picture is not yet complete.

For a 78-year-old, this difference is largely irrelevant — TAVR will almost certainly outlast the clinical horizon. For a 58-year-old who may live another 30 years, the calculus changes. If a TAVR valve deteriorates in 15 years, the patient will need another intervention. A valve-in-valve TAVR (placing a new TAVR valve inside the old one) is an option, but it is technically more demanding and may not be feasible depending on the original valve size. Surgery to replace a failed TAVR valve carries higher risk because of adhesions from the first procedure.

This is the central trade-off for younger patients: TAVR's better short-term recovery vs surgery's longer track record of durability.

How standardized endpoints made the evidence trustworthy

Comparing results across trials requires consistent definitions of what counts as a stroke, a major bleed, or valve failure. The Valve Academic Research Consortium (VARC) published standardized endpoint definitions for TAVR trials in 2012 — VARC-2 — co-authored by researchers at Columbia University including Ajay Kirtane [6]. These definitions enabled valid comparison of PARTNER 3, SURTAVI, and other low-risk TAVR trials, and are now standard in structural heart disease research worldwide.

What is changing

TAVR volumes now surpass surgical valve replacement in the United States for the first time. Technology continues to improve: newer-generation valves have lower pacemaker rates, less paravalvular leak, and better repositionability. Transfemoral access (through the groin) is now achievable in more than 90% of patients with modern hardware.

Guidelines from the American College of Cardiology and American Heart Association now support either TAVR or SAVR as a Class I recommendation for patients over 65 at low surgical risk, and TAVR for most patients over 80. For patients under 65, SAVR is still generally preferred at experienced centers where long-term follow-up is available, but a shared decision-making approach — discussing valve durability, recovery time, and lifestyle priorities — is increasingly standard.

Questions to ask your cardiologist or cardiac surgeon

• What is my STS surgical risk score, and what does it mean for my procedure choice?
• Am I anatomically suitable for a transfemoral TAVR approach?
• Given my age, how should I weigh TAVR's faster recovery against surgery's longer durability record?
• If a TAVR valve needs to be replaced in 15 years, what are the options at that point?
• What is your center's volume of TAVR and SAVR procedures per year?
• What new pacemaker risk am I facing with each option, and does that matter given my current heart rhythm?
• Is my anatomy better suited to a balloon-expandable or self-expanding TAVR valve?

The bottom line

For patients who are older, frail, or at elevated surgical risk, TAVR has become the clear preferred approach — it matches or exceeds surgical survival while drastically reducing recovery time and procedural trauma. For younger, lower-risk patients, both options are now guideline-supported, but the decision is more nuanced. A 75-year-old in otherwise good health will almost certainly do at least as well with TAVR as with surgery, with a much easier recovery. A 60-year-old with a 30-year life expectancy faces genuine uncertainty about whether TAVR valves will last as long as surgical ones. The right answer depends on your anatomy, your priorities, your center's experience, and honest conversations about what the long-term data can and cannot yet tell us.